Shares of CSL (ASX:CSL) fell 1% in recent Tuesday trade after the Australian National Audit Office said in a Monday statement that the procurement of onshore manufacturing capability for antivenoms and vaccines by the company's unit Seqirus "did not maximize value for money for the Australian taxpayer in the long term."
The office said the procurements needed earlier planning and clearer value-for-money conclusions.
CSL did not immediately respond to MT Newswires' email request for comment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments